Back to News
Market Impact: 0.2
BTIG Initiates Coverage of ORIC Pharmaceuticals at Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
BTIG initiated coverage of ORIC Pharmaceuticals (NASDAQGS: ORIC) on September 23, 2026, with a Buy recommendation. The initiation is a positive external endorsement for the U.S.-based biotechnology company, although the article provides no price target, valuation rationale, or clinical-development details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ORIC0.50
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- Top Wall Street analysts like these 3 dividend stocks for consistent income
- Crocs evp Rupert Campbell sells $399K of CROX stock
- MercadoLibre's Profits Fall Again. What It Means for Investors